CheckMate49828 was an open-label phase III study in which newly diagnosed GBM patients with unmethylated MGMT (O6-methylguanine-methyltransferase) promoter were randomized 1:1 to receive RT + nivolumab vs RT + temozolomide (according to Stupp protocol).2 Overall, 560 patients were enrolled. The gene discussed is MGMT; the disease is glioblastoma.